The setting of HER2-overexpressing BC is particularly suited to carry out this analysis, considering our previous results indicating that these patients, at diagnosis, retain an unaltered immune proficiency that can be exploited by NC drugs such as trastuzumab or taxanes [13]. Here, ERBB2 is linked to breast cancer.